New Rochelle, NY, January 22, 2013--A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers (http://www.
Elizabeth Pratico, Bruce Sullenger, and Smita Nair, Duke University Medical Center, Durham, NC, describe the innovative techniques they used to create an aptamer--a short sequence of nucleic acids--that binds to the human protein OX40, a costimulatory molecule present on the surface of already activated immune cells.
In the article "Identification and Characterization of an Agonistic Aptamer Against the T Cell Costimulatory Receptor, OX40," (http://online.
"The therapeutic potential of aptamers has always been one of their most promising aspects," says Executive Editor Fintan Steele, PhD, SomaLogic, Inc., Boulder, CO. "This elegant work by the Duke team underlines that promise while extending it into the critical area of immunotherapy."
Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Fintan Steele, PhD (SomaLogic, Boulder, CO).
About the Journal
Nucleic Acid Therapeutics (http://www.
About the Publisher
Mary Ann Liebert, Inc., publishers (http://www.
Mary Ann Liebert, Inc.
140 Huguenot St., New Rochelle, NY 10801-5215
Phone: (914) 740-2100
Fax: (914) 740-2101